Verdict in DePuy Pinnacle Hip Lawsuit Reduced To $151M, But Additional Trials to Proceed

A federal judge indicates that a verdict against Johnson & Johnson’s DePuy Orthopaedics division over alleged problems with Pinnacle hip implants will stand, but the amount of damages awarded by the jury will be reduced from $500 million to $151 million for five plaintiffs whose cases were tried together. 

U.S. District Judge Ed Kinkeade said he was forced to reduce the jury’s award of punitive award in a DePuy Pinnacle hip trial, pursuant to Texas state laws, which limit the amount of such damages that may be awarded to punish corporations. However, Judge Kinkeade refused to set the verdict aside or allow the manufacturer to have a new trial.

After hearing evidence involving complications suffered by five different individuals who received the controversial metal-on-metal hip implant, the jury awarded a combined $140 million in compensatory damages, as well as another $360 million in punitive damages.

Learn More About

DePuy ASR Hip Lawsuits

Lawsuits are being reviewed for several different dangerous and defective hip replacement systems.


Johnson & Johnson argued that the verdict should be thrown out, or in the alternative indicated that the $360 million in punitive damages should be reduced to about $10 million.

The verdict came in the second bellwether trial scheduled in a federal multidistrict litigation (MDL) established for cases filed throughout the federal court system, which are centralized before Judge Kinkeade in the Northern District of Texas.

All of the complaints raise similar allegations, indicating that the DePuy Pinnacle hip replacement was defectively designed, prone to fail and caused metal blood poisoning, known as metallosis, often resulting in the need for risky revision surgery to have the hip implant removed or replaced after just a few years.

Johnson & Johnson received a defense verdict in the first DePuy Pinnacle trial to go before a jury in 2014, after the manufacturer argued that the plaintiff’s implant was improperly positioned by the surgeon. However, the jury in this case concluded that each of the plaintiffs’ injuries were caused by defects and problems with the DePuy Pinnacle hip implant design.

Judge Kinkeade also issued an order (PDF) on July 5 refusing a request by Johnson & Johnson and DePuy to stay additional Pinnacle hip bellwether trials while the most recent verdict is appealed, noting that numerous courts have held that it is normal for the MDL process to continue during an appeal.

A series of bellwether trials in the DePuy Pinnacle hip litigation are expected to move forward, serving as test cases for thousands of similar lawsuits pending nationwide for individual who experienced problems with the implant.

The next trial is scheduled to begin on September 6, and will be selected from a pool of seven cases.

Metal-on-Metal Hip Implant Problems

The Depuy Pinnacle is a metal-on-metal hip replacements, which features a metal femoral head that rotates within a metal acetabular cup. Similar models have been introduced by several different manufacturers in recent decades, and the design has been linked to substantial problems, often resulting in catastrophic failure within a few years after the artificial hip is implanted.

Most of the devices were introduced through the controversial fast-track 510(k) approval process, which only required that the device be a “substantial equivalent” to an already existing device approved by the FDA. However, the snowball effect of the substantial equivalence test has allowed many devices now considered unreasonably dangerous and defective to be implanted in thousands of Americans.

Unlike other artificial hip designs, which typically feature metal-on-ceramic or metal-on-plastic, the metal-on-metal hips have been found to release microscopic metallic debris as the parts rub against each other. This has been linked to reports of loosening and failure, often within a few years after the artificial hip is implanted.

The FDA released new guidance for metal-on-metal hip replacements in January 2013, indicating that doctors should only use the design if other artificial hip implants are not appropriate. The agency also determined that future metal-on-metal hip designs will be required to undergo extensive human clinical trials before they will be approved.

Thousands of metal-on-metal hip replacement lawsuits have been filed in recent years throughout the U.S., alleging that the manufacturers failed to adequately research the design or warn about the large number of implants that were failing within a few years and requiring revision surgery.

Johnson & Johnson previously agreed to pay more than $2.4 billion to settle DePuy ASR hip lawsuits faced by their subsidiary, resolving about 8,000 cases brought by individuals who required revision surgery after receiving this newer metal-on-metal design, which was recalled from the market after a higher-than-expected failure rate became evident.

Although the DePuy ASR design was based on the Pinnacle hip, Johnson & Johnson has failed to negotiation a large settlement for DePuy Pinnacle hip lawsuits, previously indicating that it intends to defend the cases at trial.



Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL
Leadership Development Committee for Suboxone Dental Injury Lawyers Established in Federal MDL (Posted yesterday)

The U.S. District Judge presiding over all Suboxone lawsuits has created a mentorship program to use the litigation to provide some attorneys an opportunity to gain experience in handling complex federal multidistrict litigations.

Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M
Gilead Settlement Resolves 2,625 HIV Drug Lawsuits Pending in Federal Courts for $40M (Posted 3 days ago)

Gilead says it will pay $40 million to resolve HIV drug lawsuits over Truvada, Atripla, Viread, Stribild and Complera pending in the federal court system, involving claims that the the company sat on safer formulations of the drugs for years to increase profits.